Promising preclinical data with its RNAi-based platform in liver and bladder cancers, combined with an early stage collaboration, sent MDRNA Inc. skyrocketing Wednesday in what could be a sign of news to come from the Bothell, Wash.-based company in 2010. (BioWorld Today)
KaloBios Pharmaceuticals Inc. started off the year - and the annual J.P. Morgan conference - on a high note, partnering its Humaneered antibody fragment targeted against Pseudomonas aeruginosa infections with Paris-based Sanofi Pasteur in a potential $290 million deal. (BioWorld Today)
Privately held Icon Bioscience Inc., which has flown under the radar since it was founded in 2007, wanted to wait until it had proof of its drug delivery technology for controlled-release ophthalmic products before emerging on the public scene. (BioWorld Today)
Though 2009 has passed (finally), the year saw a number of regulatory filings - Danbury, Conn.-based Biodel Inc.'s new drug application for Viaject injectable insulin made it just under the wire with a Dec. 30 submission - that make for some much-awaited action dates in the first half of 2010. (BioWorld Today)
Basilea Pharmaceutica AG's antibiotic ceftobiprole failed for the third time to clear FDA review due to data integrity issues, news that sent shares falling 15 percent but could give the Swiss company more ammunition in its ongoing arbitration process claiming damages against partner Johnson & Johnson. (BioWorld Today)
